Tolerogenics

Tolerogenics is a public-private partnership venture with the Luxembourg Institute of Health (LIH), an excellent scientific hub in the field of immunology. Established in 2016, it specializes in therapies for allergies and autoimmune diseases. This Luxembourg-based biotech company has developed a tolerance-inducing allergen-specific immunotherapy setting up the function of Tregs – regulatory T cells that can suppress an immune response so as to maintain self-tolerance.

Tolerogenics is always finding out solutions to meet the medical demands for the treatment of allergies and autoimmune diseases. The current treatment options show shortcomings in the fields of safety, effectiveness and patient compliance. Therefore, it is providing a novel tolerance-based approach to enable a safe, efficient and lasting cure for allergy and autoimmune diseases with a patient-friendly treatment protocol. For the induction of tolerance, this company has developed novel and patent-protected key technologies, which can be used in combination with the established allergen, or autoantigen-specific immunotherapy or to change new treatment options.

"Cure – not only treatment of symptoms" is the main vision of Tolerogenics. It aims to become an international leading biotech company in the development of the most effective therapy options for allergy and autoimmune diseases. This company always believes in creative scientists and sophisticated management to help patients worldwide live a better life.

Founded: 2016

Headquarters: Luxembourg City, Luxembourg

Website: https://tolerogenics.lu/